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Long non-coding RNAs harboring 
miRNA seed regions are enriched in 
prostate cancer exosomes
Alireza Ahadi1,2, Samuel Brennan3, Paul J. Kennedy2,4, Gyorgy Hutvagner2 & Nham Tran2,5
Long non-coding RNAs (lncRNAs) form the largest transcript class in the human transcriptome. These 
lncRNA are expressed not only in the cells, but they are also present in the cell-derived extracellular 
vesicles such as exosomes. The function of these lncRNAs in cancer biology is not entirely clear, but they 
appear to be modulators of gene expression. In this study, we characterize the expression of lncRNAs 
in several prostate cancer exosomes and their parental cell lines. We show that certain lncRNAs are 
enriched in cancer exosomes with the overall expression signatures varying across cell lines. These 
exosomal lncRNAs are themselves enriched for miRNA seeds with a preference for let-7 family members 
as well as miR-17, miR-18a, miR-20a, miR-93 and miR-106b. The enrichment of miRNA seed regions in 
exosomal lncRNAs is matched with a concomitant high expression of the same miRNA. In addition, the 
exosomal lncRNAs also showed an over representation of RNA binding protein binding motifs. The two 
most common motifs belonged to ELAVL1 and RBMX. Given the enrichment of miRNA and RBP sites on 
exosomal lncRNAs, their interplay may suggest a possible function in prostate cancer carcinogenesis.
For many decades, cancer has been thought as a disease resulting from DNA damage. More than often, these 
resulting DNA products are aberrantly overexpressed or deleted in an individual to promote the growth of cancer 
cells. Although these protein-coding genes have been widely characterized for their role in tumorigenesis, these 
DNA regions represent only 2% of the human genome. A large proportion is non-coding and its expression and 
function have been forgotten until the discovery of non-coding RNAs.
The term non-coding RNA (ncRNAs) is commonly associated with RNA which is not translated into a pro-
tein. Indeed many ncRNAs are now understood to have important biological regulatory functions which regulate 
gene expression at multiple steps/levels1. NcRNAs can be divided into two groups encompassing the small and 
long ncRNA families. The small RNA contingent is approximately 18–29 nucleotides in length and common 
members include small interfering RNAs (siRNAs), microRNAs (miRNAs) and PIWI associated RNAs (piRNAs).
The lncRNAs can range from several hundred to kilobase size species and evidence now suggests that large 
non-coding regions of the human genome are transcribed during normal and diseased cellular function2–4. These 
ncRNAs are regulated by distinct promoters, display dynamic spatial temporal expression and regulate protein 
coding genes central to development and oncogenesis5,6. In addition, the expression of lncRNAs is dysregulated 
in many cancers such as breast, colon, liver and also prostate cancer7.
Prostate carcinoma represents one of the biggest challenges to the scientific and clinical community as it 
remains the most common malignancy in men in the western world, where it is still the second leading cause of 
cancer death8. Even though prostate cancer remains a worldwide problem, the exact mechanisms orchestrating 
the development and progression of prostate cancer are complex and ill defined.
Due to the heterogeneous nature of the disease, this has impeded the discovery of effective clinical markers 
and the development of novel therapies. The majority of studies to understand this disease have focused on pro-
teins, mRNAs and miRNAs. However, there is limited data on the characterization of the lncRNAs and their role 
in prostate cancer.
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One of the first lncRNAs described in prostate cancer was the prostate cancer antigen 3 (PCA3)9. This lncRNA 
was over expressed in the tumor areas when compared to adjacent normal prostate tissue. However the exact 
function of PCA3 remains to be determined.
More recently, exosomes10 have become important factors in our understanding of tumourigensis11. These 
microvesicles typically 50–150 nm in size are released into the extracellular environment to facilitate communica-
tion between cells. Despite their small size, exosomes are enriched in bioactive molecules such as RNA, miRNAs 
and proteins. It has been demonstrated that tumour derived exosomes shuttle RNA to cells within the tumor 
environment to promote tumor growth and dampen the immune response12.
Our study examines the expression of lncRNAs in several prostate cancer cell lines but also measures the levels 
of these lncRNAs in the released exosomes. We show that specific lncRNAs are enriched in cancer exosomes and 
furthermore these sequences harbour miRNA seed regions and appear to be enriched for specific RNA binding 
motifs.
Results
Verification of prostate cancer exosomes. This study used four common prostate cancer cell lines 
(PC3, VCaP, LNCaP, DU145) and one normal epithelial line (PNT2) to characterize the expression of exoso-
mal lncRNAs. We isolated these exosomes using ultracentrifugation13 and then verified these exosomes using 
Transmission EM, nanoparticle tracking followed by detection of specific transmembrane proteins CD9, CD63, 
TGS101 and intracellular AGO2 with the Europium assay (Fig. 1)14. Transmission EM for one of the represent-
ative prostate cancer line DU145 show exosomes ranging from 100–150 nm in size. Nanoparticle tracking of 
these vesicles indicates that the majority of particles are 145 nm. We then measure the presence of several pro-
teins, which are commonly enriched in exosomes. For exosomes derived from DU145 and the normal cell line 
PNT2, CD9, CD63, and TGS101 were detected. The AGO2 protein is typically not found or under-represented in 
exosomes and this was not detected in our isolated exosomes.
Long ncRNAs are found in prostate cancer exosomes. LncRNA expression was then examined in 
these exosomes and their parent cell lines. This was performed using a Human 8 × 60 K LncRNA expression 
array (ArrayStar, Rockville, USA) which contained 33,045 LncRNAs and 30,215 coding transcripts. Results from 
Figure 1. Characterisation of exosomes from in vitro cell culture. (A) Representative TEM image of DU145 
exosomes at 7900 magnifications. White arrows depict exosomes of ~100 μ m with kidney bean like appearances. 
(B) Representative particle tracking of a DU145 exosomes using the NanoSight Instrumentation. (C) Detection 
of exosome surface markers, CD9, CD63, TSG101 and AGO2 in DU145 and PNT2 cells. Absorbance was 
measured by the release of europium using a modified ELISA36. (D) Small RNA bioanalyser chip image showing 
the presences of small ncRNAs between 21 and 27 nts (black arrows).
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the array suggested that hundreds of lncRNAs are readily found in exosomes released from prostate cancer cells. 
We applied a two-fold threshold for expression to identify the most abundant and common lncRNAs in these 
exosomes and their parent cells (Tables 1 and 2 respectively). The Venn diagram shows that 26 lncRNAs enriched 
and common to these prostate cancer exosomes (Fig. 2A).
Hierarchical clustering (HCL) analysis of the exosomal lncRNAs indicated that the populations of these lncR-
NAs could discriminate a normal cell line (PNT2) from a prostate cancer cells (Fig. 2B). The result may suggest 
that exosomes harbor unique populations of lncRNAs which represent the physiological conditioning of the cell, 
i.e. diseased versus a normal phenotype.
miRNA expression profiles in prostate cancer exosomes and cells. We furthered examined the 
miRNA expression in both exosomes and cells in prostate cancer cells and healthy cells using an Affymetrix 
miRNA microarray GeneChip® platform. Using Euclidean metrics for HCL analysis, clustering was initially per-
formed on the exosomal data alone, followed by the analysis on the cellular data and lastly combining the two 
data sets. In the first analysis, the exosomal miRNAs could separate out the four different prostate cancer cell lines 
from the normal PNT2 line. The VCaP and LNCaP cells branch off a common node, which suggest they may have 
similar populations of exosomal miRNAs. In contrast, the DU145 and PC3 are unrelated (Fig. 3A). Whereas the 
clustering pattern in the cellular miRNAs suggests that DU145 shares some commonality with the PNT2 cells. 
However PNT2 is still distinct when compared to the other three cancer cell lines (Fig. 3B).
When combining the two data sets there are two major clusters, exosomes and cells. The cellular signature of 
PNT2, DU145, LNCaP and PC3 are distinct from their exosomal miRNAs (Fig. 3C). Furthermore, Pearson’s cor-
relation coefficients indicated that the miRNA expression is highly correlated between cancer cells and exosome 
(Table 3). This correlation was considerably lower for the normal cells.
Specific prostate cancer cells contain exosomal lncRNAs which are enriched with different 
miRNA seed regions. To further understand the role of these exosomal lncRNAs, we hypothesized that 
they harbored miRNA seed regions as to sequester and bind mature miRNA sequences. To identify these motifs, 
we performed the enrichment analysis for each of the four cell lines. The data was filtered before analysis and only 
included transcripts, which were highly enriched in the exosome of each cell line. Several motifs were identified 
and then aligned to known miRNA sequences. Any motifs, which did not show perfect seed region alignment, 
were discarded from further analysis.
Gene name VCaP LNCaP DU145 PC3 Long ncRNA type
ENST00000501280 62.0 21.4 21.4 14.7 bidirectional
uc010bys.1 28.7 11.0 11.0 14.6 intergenic
uc001qgn.1 50.0 5.4 5.4 3.0 intronic antisense
ENST00000499690 15.4 16.2 16.2 8.5 intronic antisense
ENST00000453968 48.5 2.5 2.5 2.3 intergenic
G36642 46.0 3.0 3.0 2.2 intronic antisense
AK055500 39.1 3.5 3.5 6.1 intergenic
HIT000070262 44.2 2.7 2.7 2.1 natural antisense
ENST00000452932 11.8 9.5 9.5 7.7 intergenic
chr13:38754175-38773200+ 25.6 3.7 3.7 2.8 intergenic
nc-HOXB1-156- 7.4 8.4 8.4 2.6 intergenic
ENST00000471393 18.5 2.3 2.3 3.5 intergenic
ENST00000412906 20.0 2.2 2.2 2.1 intronic antisense
ENST00000392478 3.7 6.2 6.2 2.0 intronic antisense
AY927529 7.0 2.6 2.6 5.8 exon-sense overlapping
ENST00000426885 5.8 3.3 3.3 4.5 Intergenic
AK123811 2.3 3.7 3.7 4.9 intergenic
ENST00000402340 5.7 2.3 2.3 3.7 intergenic
ENST00000509526 4.9 2.3 2.3 3.4 intergenic
ENST00000412347 4.1 2.5 2.5 3.0 intergenic
chr9:137160729-137173954- 3.8 2.4 2.4 2.8 intergenic
ENST00000411341 3.3 2.3 2.3 3.2 intergenic
ENST00000430245 2.8 2.9 2.9 2.4 intronic antisense
ENST00000508864 3.9 2.4 2.4 2.1 intergenic
uc001upm.2 2.2 2.0 2.0 4.3 intergenic
ENST00000500478 3.2 2.2 2.2 2.3 intergenic
Table 1.  Common lncRNAs which are enriched in the exosomes of all four prostate cancer cell lines (VCaP, 
LNCaP, DU145 and PC3). The threshold cut-off was a fold change greater then 2. Fold change was defined 
as the ratio of normalized intensities between two samples (exosome versus cell), positive value indicates up-
regulation.
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Gene name VCaP LNCaP DU145 PC3 lncRNA type
AK098134 − 48.6 − 3.5 − 3.5 − 14.1 intergenic
uc.63- − 18.6 − 3.4 − 3.4 − 9.6 intron sense-overlapping
uc004exm.2 − 7.2 − 2.1 − 2.1 − 22.2 intergenic
ENST00000513351 − 23.2 − 2.4 − 2.4 − 4.3 intergenic
BC008292 − 10.9 − 2.7 − 2.7 − 2.7 bidirectional
BC131500 − 4.1 − 5.0 − 5.0 − 2.0 intronic antisense
AK125090 − 6.5 − 2.6 − 2.6 − 3.5 intergenic
ENST00000366160 − 3.0 − 3.4 − 3.4 − 5.2 intergenic
NR_002998 − 3.5 − 2.0 − 2.0 − 7.2 intron-sense overlapping
G43604 − 4.0 − 3.2 − 3.2 − 2.9 natural antisense
NR_024413 − 4.1 − 2.0 − 2.0 − 3.9 intron-sense overlapping
uc003hqg.1 − 5.3 − 2.1 − 2.1 − 2.4 intronic antisense
uc003eub.2 − 3.6 − 2.0 − 2.0 − 4.1 intergenic
NR_024334 − 2.7 − 3.3 − 3.3 − 2.5 natural antisense
uc003nov.3 − 3.1 − 2.6 − 2.6 − 2.4 intergenic
ENST00000429037 − 2.6 − 2.4 − 2.4 − 2.6 intergenic
HIT000097222 − 2.7 − 2.1 − 2.1 − 3.3 natural antisense
AK097323 − 2.0 − 2.7 − 2.7 − 2.2 natural antisense
NR_002836 − 2.2 − 2.4 − 2.4 − 2.3 intergenic
Table 2.  LncRNAs which are in common and enriched in the four cell lines. Fold change was defined 
as above but in this instance, fold change represent (cell versus exosome). Negative values indicate down-
regulation.
Figure 2. (A) Venn diagram showing the common exosomal lncRNAs between the PC3, DU145, LNCaP and 
VCaP prostate cancer cell lines. (B) Heat map showing the expression of exosomal lncRNAs in prostate cancer 
cells and a normal cell line (PNT2). Red denotes high expression and aqua denotes reduced expression of the 
lncRNAs.
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Figure 3. (A) miRNA heatmap in exosomes representing prostate cancer and PNT2 normal cell lines. Aqua 
colour represents reduced levels and Red is indicative of high expression. (B) Differential expression of miRNAs 
in the parental five cell lines. (C) Heatmap showing the expression of miRNA in both exosomes and their 
parental cell line.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:24922 | DOI: 10.1038/srep24922
By using the miRNA expression data, we then measured the miRNA levels in these prostate cancer exosomes 
and identified the extreme fold change in expression values for these miRNAs in each cell line. In the next step, 
these motifs were then mapped to the miRNAs showing the highest fold change to identify a perfect seed region 
alignment. Interestingly, most of highly enriched motifs in each of the cell lines are aligned to at least one miRNA 
which is highly represented in the exosome of the same cell line. For example, in VCaP, out of the 31 identified 
highly enriched motifs, 14 of them showed a perfect seed match to at least one miRNA which was also highly ele-
vated in the exosome (Table 4). In the VCaP cell exosomes, the first eight identified motifs have a perfect binding 
site for the seed match of twenty highly expressed miRNAs. These correspond to let-7a, let-7b and let-7c, which 
are the top 3 highly overrepresented miRNAs found in the VCaP exosomes.
We also observe a similar phenomenon in the PC3 cell line. From the 28 identified motifs, eight of them show 
perfect reverse complementary binding site of 9 highly overexpressed miRNAs. This includes miR-221-5p, miR-
762, miR-30b, miR-30c, miR-30d, miR-185, miR-151-5p, miR-130b and miR-149* (Supplementary Table S1). 
In the LNCaP exosomes, the 28 most highly expressed miRNAs had complementary seed regions, which were 
enriched in the exosomal lncRNAs. Our analysis identified 18 motifs with U rich sequences and interestingly, 
a large number of these motifs showed perfect seed region binding sites to miRNAs belonging to two families. 
These included let-7 family members; let-7a, let-7b, let-7c, let-7d, let-7e and let-7i as well as the miR-17 family 
members including miR-17, miR-18a, miR-20a, miR-93 and miR-106b. Upon closer inspection, we observed that 
all the above-mentioned miRNAs have a perfect seed region match to the motif UGUUUU which is one of the 
most highly enriched motifs found on these exosomal lncRNAs.
When we extended our enrichment analysis to the normal PNT2 line, we identified 40 over represented motifs 
in the exosomal lncRNAs. Of these, only three motifs had seed regions to six miRNAs as well as the let-7 family. 
Concomitantly these miRNAs were also over expressed in the exosomes. Only one motif, AGCUGG was unique 
to PNT2 whose seed region is complementary to miR-149-5p. Although these motifs were not entirely unique 
to PNT2, we did observe that, exosomal lncRNAs only from cancer cells had a higher chance (3–9 fold increase) 
for seed matching.
These results suggest that lncRNAs, which are enriched in cancer exosomes, also harbor miRNA seed regions 
and there is a concomitant high representation of that same miRNA in the exosome. Furthermore we observed 
that let-7 family and miR-17 families could be associated to U rich motif overrepresented in the lncRNA tran-
scripts expressed in the exosomes.
miR-149* seed match is highly enriched in prostate cancer exosomes. From our analysis, 
(Supplementary Table S2), the motif CCUCCC has the most frequency in the exosomal lncRNA transcripts 
(Fig. 4A). This motif is a perfect seed match for ten human miRNAs; miR-7106-5p, miR-6883-5p, miR-6799-5p, 
miR-6785-5p, miR-4728-5p, miR-6887-5p, miR-6885-5p, miR-6799-5p, miR-328-5p and miR-149*.
Out of these ten miRNAs, the only miRNA which we had the expression data available was for miR-149*. 
When we examined the levels of miR-149* in the exosomes, we realized that the level of this miRNA is sig-
nificantly (p value = 0.001) high in DU145, LNCaP, PC3 and VCaP with 4.52, 4.03, 3.28 and 1.5 fold change 
difference respectively (This fold change was the level of miR-149* in the exosome relative to its parent cell). Our 
observation may suggest that the enrichment of miR-149* seed match motif found in the exosomal lncRNAs is 
directly related to the high level of miR-149* also found in the exosomes of the prostate cancer cells. To demon-
strate the motif is unique to exosomal lncRNAs only, we performed an additional enrichment analysis on exoso-
mal lncRNAs compared to the cellular lncRNAs (control set, Table 2) and identified the same motif (Fig. 4B). We 
then performed the same analysis on the normal prostate cell line and did not find this motif. Thus it is missing in 
the transcripts of exosomal lncRNAs of PNT2 cells.
Prostate cancer cells harbor common motifs in their exosomal lncRNAs. Our next analysis 
was to identify motifs, which are highly abundant in the common exosomal lncRNAs between all four prostate 
cancer cell lines compared to common cellular transcripts of the same four cell lines. This search yielded 40 
motifs in the exosomal lncRNAs, which harbored a perfect reverse complementary seed match to 697 miRNAs 
(Supplementary Data S3). Of these motifs, 33 are unique to prostate cancer cells when compared to the PNT2 
line. We adopted the same approach for the common lncRNA cellular transcripts and identified only one motif 
with the sequence of GGGCGC. Interestingly, this motif was not enriched in any of the exosomal lncRNAs from 
either the cancer or normal cells.
miRNA seed region enrichment in the exosomal lncRNA is independent of sequence 
length. To investigate if sequence length was a determinant in miRNA seed enrichment, we compared the 
Cell line
Pearson’s correlation coefficient of 






Table 3.  Correlation of miRNA expression between the parental cell and the exosome: All correlations are 
significant at 0.01 level (2-tailed).
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AUUUUU 28 distinct miRNAs NA


















CCCAGC 4 distinct miRNAs NA
CCAGGC 4 distinct miRNAs NA
CCUGGG 16 distinct miRNAs NA
CCCAGG 6 distinct miRNAs NA
CCUCCU hsa-miR-149-3p 9.46
CUGGGA 11 distinct miRNAs NA




AGGCUG 10 distinct miRNAs NA
CUCCAG 8 distinct miRNAs NA
CCUCAG 11 distinct miRNAs NA





GCCCAG 9 distinct miRNAs NA
UGGGAG 13 distinct miRNAs NA
GGGAGG 20 distinct miRNAs NA
CUUCCU hsa-miR-149-3p 9.46














Table 4.  Overrepresentation of miRNA seed region motifs in highly enriched exosomal lncRNAs from 
the VCaP cell line. Fold change of the miRNAs is shown in the last column. Note: All motifs listed in the table 
represent the perfect reverse complementarity to the seed region of specific miRNAs.
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average length of all exosomal lncRNAs to the cellular lncRNAs in each cell line. Performing one way ANOVA 
test, we observed that lncRNAs in the exosomes of VCaP and LNCaP cells were significantly (p value = 0.001) 
longer than the average length of lncRNAs found inside their parent cells. Further, the DU145 cells did not show a 
significant mean difference between the length of exosomal and cellular transcripts (p value = 0.28), even though 
the average length of exosomal lncRNAs is 150 bp longer than the average length of its’ cellular transcripts. In 
contrast, in the PC3 cells, the mean length of exosomal lncRNAs was considerably less (570 bp difference) than 
the mean length of cellular lncRNAs. Performing Kendall’s tau-b two-tailed test in SPSS statistical tool, we found 
no strong correlation between lncRNA sequence lengths and miRNA seed enrichment (Table 5). These analyses 
suggest that miRNA seed enrichment in the exosomal lncRNAs was independent of sequence length and may 
suggest the enrichment is linked to exosomal transport of the lncRNAs from the cell.
Exosomal lncRNAs are enriched with specific RBP binding sites. We then sought to investigate if 
there existed short motifs, which could associate with RNA binding proteins. Our first analysis was restricted 
to the exosomal lncRNAs. We performed RBP binding site enrichment analysis on different sets of exosomal 
lncRNAs transcripts including lncRNAs which are enriched in all prostate cancer cell lines (N = 26), lncRNAs 
which are enriched in the exosome of healthy prostate cells (N = 32), and the set of lncRNAs which are enriched 
in the cell of at least one prostate cancer cell line (N = 141, Supplementary Table S5), and the exosomal lncRNAs 
enriched in each prostate cancer cell line. Towards this end, we aligned the genomic sequence of these exosomal 
lncRNAs to the RNA binding protein database (RBPDB)15. This database is a collection of 424 experimentally 
validated human RNA-binding sites collected from literature, which includes 73 position-based matrix (PWM). 
We used the RBPDB default value 0.8% as the minimum threshold score for any matches between identified 
motifs in our given sequences and RNA-binding sequence in the database. We identified a total number of 38 
RBPs with confident binding sites (Supplementary Data S4). Each of these RBPs has a different number of bind-
ing sites on the exosomal lncRNAs. However, RBMX, SFRS1 and ELAVL1 have the highest number of confident 
binding sites. To confirm this finding using our algorithm, we identified 33, 42, 63 and 28 motifs (six bases in 
size), which were highly enriched in VCaP, PC3, LNCaP and DU145 cells respectively (Supplementary Data S6). 









All exosomal transcripts 26 0.52 weak
All cellular transcripts 19 0.16 negligible
All over expressed transcripts in 
cancer exosomes 141 0.42 weak
All over expressed transcripts in 
cancer cells 151 0.24 negligible
All correlations are significant at 0.01 level.
Table 5.  Kendall’s tau-b two tailed test result for correlation analysis of the length of transcripts and motif 
enrichment frequency.
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These short nucleotide sequences represented 126 distinct motifs which from 43 are binding sites for at least one 
of the following RBPs: EIF4B, ELAVL1, KHDRBS3, MBNL1, PABPC1, SFRS1, SFRS9 and RBMX. The number of 
positive matching RBP binding sites found in the exosomal lncRNAs for cancer cell line is shown in Fig. 5A–D. 
Our analysis shows that there is a clear over representation of motifs for ELAVL1, PABPC1, SFRS1 and RBMX 
(Fig. 5E). Using our algorithm, we also observed the over-representation of the binding sites of RBMX, SFRS1 and 
ELAVL1 in the set of enriched exosomal lncRNAs in cancer cell lines and in the healthy cells.
Comparative RBP site enrichment analysis in exosomal lncRNAs and cellular lncRNAs. Using 
our algorithm, we then examined if the over-represented motifs in the exosomal transcripts compared to cellular 
transcripts shows a significant reduction in the binding site availability for RBPs. Using a set of 19 lncRNAs which 
were common to all cancer cell lines but not enriched in exosomes (Table 2), we found a significant reduction 
(p value = 0.001) in enriched binding sites for both RBMX and ELAVL1 (Fig. 6A). We then extended this analy-
sis by comparing lncRNAs which were enriched in the exosome (141 transcripts) to those lncRNAs which were 
highly expressed in the cells (151 transcripts) of at least one cancer cell line (Supplementary Table S5). This com-
parative analysis identified binding sites for four distinct RBPs, RBMX, SFRS1, SFRS9 and EIF4B. However there 
is a ~50% reduction in the frequency of these binding sites for the cellular lncRNAs (Fig. 6B).
Figure 5. The number of positive matching RBP binding sites found in the exosomal lncRNAs for each cell line 
(A) VCaP, (B) PC3, (C) LNCaP, (D) DU145, (E) Distribution of RNA binding sites in exosomal lncRNAs of at 
least one cancer cell line.
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Our analysis on the enrichment of healthy cells also shows significant reduction of the binding site of these 
RBPs in the highly enriched lncRNAs of exosomes compared to the ones in the cells. We did not identify any RBP 
which uniquely target either the exosomal or the cellular lncRNAs, however there is a significant difference in the 
number of binding sites for RBMX, ELAVL1 and SFRS1 in the exosomal lncRNAs compared to cellular lncRNAs 
of both healthy and cancer cell lines.
Discussion
This study measured the levels of long non-coding RNAs in exosomes released from prostate cancer cells and 
healthy cells. The four prostate cancer cell lines represent common metastatic lines isolated from different tissue 
sites. They have different metastatic potential and are either hormone sensitive/resistant. The array data indicated 
that lncRNAs are present in abundance in both healthy and prostate cancer exosomes. Furthermore, certain 
lncRNAs are specifically enriched only in the exosomes. When we applied HCL analysis, these exosomal lncR-
NAs were able to cluster the normal cell (PNT2) from the cancer cell lines. More so, LNCaP and PC3 have similar 
expression when compared to the DU145 and VCaP cells. We put forward the idea that exosomal lncRNAs sig-
natures may represent a unique set of ncRNAs, which can be exploited for biomarker research. There have been a 
plethora of studies suggesting lncRNAs as biomarkers for prostate cancer, but only a few studies have character-
ized their presence in exosomes16,17. This is one of the few studies to catalogue the many thousands of exosomal 
lncRNAs in prostate cancer cells with a comparative analysis to normal epithelia cells.
Figure 6. Comparison of RNA binding motifs on exosomal lncRNAs versus cellular transcripts.  
(A) Reduction of RBP motifs in cellular lncRNAs which are common to all four cell lines. In contrast there 
is a increase of these motifs in the exosomal lncRNAs. (B) Increase in RBP motifs of the enriched exosomal 
lncRNAs (141 transcripts) to those lncRNAs, which were highly expressed in the cells (151 transcripts) of at 
least one cell line. This analysis yielded four major binding sites for, RBMX, SFRS1, SFRS9 and EIF4B.
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Several studies have suggested that lncRNAs can act as sponges for miRNAs18,19. We extended this idea and 
sought to investigate if these exosomal lncRNAs contained any miRNA seed regions. Firstly, we identified enrich 
motifs in the exosomal lncRNAs and then mapped these motifs to only highly expressed miRNAs found in the 
same exosomes. We found that most of the enriched motifs were perfectly aligned to (seed regions) of at least 
one exosomal miRNA from the same parent cell line. In the VCaP exosomes, there was seed enrichment in their 
lncRNAs for the let-7 family members. While in the LNCaP exosomes seeds sequences for let-7 and miR-17 
members were highly represented on the exosomal lncRNAs. Another study demonstrated that let-7 was highly 
expressed in the blood of prostate cancer patients and also enriched in the exosomes of PC3 cells20. Furthermore 
there is now evidence that let-7 can be selectively package into exosomes derived from metastatic gastric cancer 
cell lines21.
Upon further analysis, we found 40 motifs with perfect miRNA seed regions, which were highly represented 
in the exosomal lncRNAs. In contrast only a solitary motif was identified in the cellular lncRNAs. In particu-
lar, CCUCCC was highly abundant with this region corresponding to the miR-149* seed. Interestingly, miRNA 
expression data indicated that miR-149* was significantly (p value = 0.001) elevated only in the exosomes and not 
the cell lines. The apparent enrichment of seed regions may suggest a possible role for these exosomal lncRNAs as 
RNA sponges for specific miRNAs.
RNA-binding proteins (RBPs) are important regulators of many post-transcriptional events, including RNA 
splicing, transport and stability. The RBP ELAVL1 (also known as HuR) tends to stabilize RNA transcripts; while 
AUF1, may induce rapid degradation of RNA transcripts22. In our analysis we identified several RBP motifs on 
these lncRNAs. The two most common motifs were associated with ELAVL1 and RBMX. These is a ~ two-fold 
increase for these sites in exosomal lncRNAs when compared to cellular lncRNAs. Furthermore we did not find 
any unique sites from our comparative analysis.
ELAVL1 is a member of the ELAVL family of RBP which posses RNA recognition motifs to selectively bind 
AU-rich elements (AREs) in the 3′ UTR regions of mRNAs. Binding of these AREs by ELAVL1 prevents the 
signalling events required for degradation thus stabilizing the mRNA transcript. It may be possible that ELAVL1 
can extend its function to bind lncRNAs with abundant AREs to stabilize the transcript. Evidence for this sce-
nario was documented when the lncRNA-UFC1 could directly interact with ELAVL1 in hepatocellular carcinoma 
cells23. ELAVL1 can also modulate transcriptome-wide miRNA binding to target RNAs in murine macrophages24. 
It was shown that transcripts bearing ELAVL1 sites proximal to a miRNA site demonstrated attenuated miRNA 
binding. There appears to be a complex interplay between miRNA binding and ELAVL1 for regulating RNA 
expression25–27.
RBMX is a ubiquitous nuclear ribonucleoprotein which interacts with the spliceosome, binds RNA, and is 
involved in pre-mRNA splicing28. It most likely binds RNA as a homodimer and is preferential to single-stranded 
5′ -CC[A/C]-rich RNA motifs. RBMX has been shown to be present in both micro particles and exosomes iso-
lated from endothelial and ovarian cancer cells29,30. A study has shown that RBMX regulates the release of TNFR1 
exosome-like vesicles into the extracellular matrix31. Their binding capacity to exosomal lncRNAs has not been 
postulated, however we predict that RBMX may mark the lncRNA into exosomes for transport akin to its func-
tion for TNFR1.
It is important to also recognize the caveats in our study. The cell lines were grown in vitro conditions to a 
confluence of 70–80% with the rationale that, it would reflect fast growing cancer cells in vivo. We have avoided 
100% confluence, as cells would likely exit this exponential growth phase. It has been shown that altering the 
growth conditions in vitro can significantly change the cellular miRNA composition32. With this in mind, we 
put forward the notion that lncRNAs along with specific RBPs act to corral these miRNAs into exosomes. Given 
that most lncRNAs harbor both seed match regions and RBP binding sites, it may be a general mechanism for 
shuttling miRNAs into exosomes.
In summary, our study has catalogued the presence of lncRNAs in exosomes from prostate cancer and normal 
cell lines. These exosomal lncRNAs seem to be enriched in exosomes and harbor both miRNA and RBP binding 
sites. The populations of exosomal lncRNAs as indicated by HCL derived from prostate cancer cells are distinct 
from normal cells. This suggests that exosomal lncRNAs are disease specific and may provide a source of bio-
markers for prostate cancer diagnosis.
The mechanism for loading exosomal lncRNAs into exosomes is currently unknown. Given the enrichment 
of distinct RBP motifs on exosomal lncRNAs, we predict that specific RBPs such as ELAVL1 may play an impor-
tant role in directing lncRNAs for exosomal transport. Many of these exosomal lncRNAs also harbored miRNA 
binding regions with an over representation for specific miRNA families such as let-7. Several lncRNAs have been 
shown to have a sponge effect33,34 and similarly these exosomal lncRNAs may partake in this regulation but with 
the added effect of transporting these miRNA into exosomes and eventual release into the extracellular milieu.
The fact that exosomal lncRNAs have both an enrichment of miRNA and RBP does elute to a possible function 
in prostate cancer cells. However, further exploration will be needed to fully understand the interplay between 
these exosomal lncRNAs, miRNAs and RBPs.
Methods
Cell lines. The prostate cancer cell lines, LNCaP, PC3, and DU145 were grown in RPMI, whereas VCaP cells 
were grown in F12:DMEM and PNT2 in defined KSFM (Invitrogen, USA). All cells were incubated at 37 °C in 
5% CO2, and supplemented with 1% v/v penicillin, streptomycin, glutamine (PSG) and 10% v/v fetal calf serum 
(FCS).
Exosome production and purification. As FCS contains exosomes of bovine origin all media were first 
depleted of these bovine exosomes. To remove bovine exosomes, we utilized the ultracentrifugation protocol 
devised by Théry, C. et al.35. First, media was constituted with all the supplements and centrifuged at 104 492 × g 
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(28 000 rpm using F40L-8 × 100 rotor (Thermo Scientific, USA)) overnight at 4 °C. Media was then filtered 
through a 0.2 μ m filter and a further 500 mL of basic media supplemented with PSG was added. Depleted media 
was stored at 4 °C for no longer than four weeks. For exosome production, cells were seeded in 175 cm2 flasks 
containing 25 mL of depleted media at an initial confluence of 15–20% and allowed to grow to 70–80% conflu-
ence, at which point the culture supernatant and cells were harvested. Once culture supernatant was harvested 
it was either stored at 4 °C for one to five days prior to exosome extraction by ultracentrifugation or frozen at 
− 80 °C and thawed the day before extraction. All exosome preparations were performed according to the pro-
tocol described by Théry et al.35 which is the current “gold standard” for exosome extraction. Confirmation of 
exosomes was performed as previously described14,36.
RNA extraction and long ncRNA arrays. RNAzol RT (Molecular Research Center, USA) was used to 
extract total RNA from both cellular and exosomal sources. Given the small size pellet for the exosomes we 
had to modify the manufacture’s protocol. In brief, 500 μ L aliquot of RNAzol RT was used to resuspend the 
exosome pellet. The same mixture was then transferred to a new pellet and resuspended. This method was used 
to concentrate the total RNA from multiple exosome pellets. Total RNA isolation was then completed using the 
manufacture’s protocol with the addition of glycogen (25 μ g) as a carrier and an overnight precipitation step. Total 
RNA was isolated from cells using the manufacture’s protocol. RNA quality was the assessed using an Agilent 
2100 bioanalyser and small RNA chip (Agilent Technologies, USA). Samples that reached the 50 ng/μ L cut-off, 
and a RIN value of 8–10 were subjected to lncRNA expression profiling. Total RNA from the exosomes and their 
parent cell were subjected to lncRNA profiling using the Human 8 × 60 K LncRNA expression array (ArrayStar, 
Rockville, USA). Each array contained 33,045 LncRNAs and 30,215 coding transcripts and required a minimum 
of 2 μ g of total RNA.
Pipeline of enriched motif identification. The algorithm used in this study takes two sets of sequences 
including exosomal (test) and cellular (control) transcripts as input and identifies a set of 6-mers which are a) 
highly enriched in exosomal transcripts compared to the cellular transcripts and b) harbor the reverse comple-
mentary match of the seed region of at least one known miRNA. For each set, a sliding window of length six scans 
the whole length of all given sequences and extracts all possible motifs of length six. The reason we selected the 
length of six nucleotides is for the importance of the miRNA seed region match in governing miRNA binding to 
the target transcript. Next, all 6-mers of each set with a frequency occurrence of one are discarded. Among iden-
tified 6-mers, those motifs which have an equal occurrence frequency in both sets are discarded. At this stage, we 
performed motif enrichment analysis on the sequences of each set using MEME37 and RSAT peak-motifs38 tools 
to validate the output of our approach. For all investigated sets of sequences in this study, we made sure that all 
discovered motifs of recently mentioned tools are indeed identified by our approach as well.
Next, among all identified motifs in each set, all motifs which show a perfect reverse complementary 
Watson-Crick match to the seed region of at least one miRNA annotated in the miRBase v2039 were identified. 
This includes 2578 distinct mature miRNA sequences. Those 6-mers which do not show a perfect match to the 
seed region of any miRNA are discarded. In seed match identification, G:U wobbles were allowed, but no bulge, 
gap or mismatch were allowed. Among all motifs identified in the sequence of exosomal transcripts, those which 
the occurrence frequency value in the exosomal set is greater than occurrence frequency value in cellular set were 
identified. The result of the last stage provide a list of short motifs harboring miRNA seed match regions in each 
set which are enriched in exosomal transcripts but are not abundant in the sequence of cellular transcripts. In 
the end, z score values associated to occurrence frequency difference distribution of identified motifs was calcu-
lated and a cut off value of three was used to identify those motifs which are extremely enriched in the sequence 
of exosomal transcripts compared to the cellular transcripts with a confidence level of 0.999. At this stage, we 
performed comparative motif enrichment analysis using the sequences of both sets using DREME40 and RSAT 
tools to validate the final output of our approach. For all investigated exosomal sets of sequences in this study, we 
made sure that all discovered enriched motifs in exosomal transcripts compared to the cellular transcripts (con-
trol) identified by DREME tool are indeed identified by our approach as well. Comparative enrichment analysis 
between two sets of genomic sequences might be affected by the length of the transcripts in each set. Generally 
speaking, a long transcript might have a higher occurrence frequency of a given motif in comparison to a control 
sequence with shuffled nucleotides. Since the comparative enrichment analysis of motifs between the exosomal 
transcript and cellular transcripts is a part of this study, we investigated the variance in lengths of input sequences 
for two sets, i.e. exosomal and cellular transcripts, is not misleading the outcome of the algorithm. We performed 
correlation analysis between the length of each transcript and the occurrence frequency of each enriched motif 
in it using Kendall’s tau-b correlation test which is suitable for non-normally distributed bivariate data. We per-
formed Kendall’s tau-b two tailed test on four different populations of selected transcripts. As could be seen in 
Table 5, the coefficient value of the investigated correlations for both cellular and exosomal transcripts indicate 
a weak correlation between the length of the transcripts and the motif enrichment. We avoided using Pearson 
and Spearman correlation analysis for two main reasons. Firstly, both these techniques are slightly sensitive to 
outliers41 and the presence of extreme values can have great influence on their correlation coefficients. Secondly, 
these tests are not appropriate for highly skewed distributions which is the case here.
Data Preparation. Genomic sequences for transcripts were obtained from Ensembl or NCBI nucleotide 
database according to their accession IDs. For those transcripts for which the genomic sequence was not availa-
ble on any publicly available database, the genomic sequence was prepared in BioPython. All poly-Adenylation 
tails were removed from the sequences in order to optimize the result of the algorithm. MicroRNA and lncRNA 
expression Heat maps were designed using CIMminer (http://discover.nci.nih.gov). The enrichment logo was 
designed using WebLogo42. The gapped enrichment sequence was designed using GLAM243.
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In order to find exosome specific lncRNAs, up-regulated transcripts with a fold change value greater than 
two in each cell line were selected. Identification of over-expressed transcripts in each cell line was performed 
by re-scaling of the expression level of each transcript using z-score transformation as described in44. The cut off 
value of three for z score was used to select transcripts which have an extreme expression value with a confidence 
level of 0.999. Over expressed miRNAs of each cell line were identified using SPSS outlier detection. In order to 
perform differential expression analysis of miRNAs in cells versus exosomes as well as correlation analysis of dif-
ferentially expressed miRNAs, all miRNA expression values were rescaled to log10 fold change.
References
1. Mattick, J. S. & Makunin, I. V. Non-coding RNA. Hum Mol Genet 15 Spec No 1, R17–29, doi: 10.1093/hmg/ddl046 (2006).
2. Jacquier, A. The complex eukaryotic transcriptome: unexpected pervasive transcription and novel small RNAs. Nat Rev Genet 10, 
833–844, doi: 10.1038/nrg2683 (2009).
3. Carninci, P. et al. The transcriptional landscape of the mammalian genome. Science 309, 1559–1563, doi: 10.1126/science.1112014 
(2005).
4. Johnson, J. M., Edwards, S., Shoemaker, D. & Schadt, E. E. Dark matter in the genome: evidence of widespread transcription detected 
by microarray tiling experiments. Trends Genet 21, 93–102, doi: 10.1016/j.tig.2004.12.009 (2005).
5. Guffanti, A. et al. A transcriptional sketch of a primary human breast cancer by 454 deep sequencing. BMC Genomics 10, 163, doi: 
10.1186/1471-2164-10-163 (2009).
6. Mercer, T. R., Dinger, M. E. & Mattick, J. S. Long non-coding RNAs: insights into functions. Nat Rev Genet 10, 155–159, doi: 
10.1038/nrg2521 (2009).
7. Rossi, S., Sevignani, C., Nnadi, S. C., Siracusa, L. D. & Calin, G. A. Cancer-associated genomic regions (CAGRs) and noncoding 
RNAs: bioinformatics and therapeutic implications. Mamm Genome 19, 526–540, doi: 10.1007/s00335-008-9119-8 (2008).
8. Parkin, D. M., Pisani, P. & Ferlay, J. Global cancer statistics. CA Cancer J Clin 49, 33–64 (1999).
9. Lu, W. et al. KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in 
prostate cancer cells than in normal prostate cells. Prostate 66, 936–944, doi: 10.1002/pros.20382 (2006).
10. Trams, E. G., Lauter, C. J., Salem, N., Jr. & Heine, U. Exfoliation of membrane ecto-enzymes in the form of micro-vesicles. Biochim 
Biophys Acta 645, 63–70 (1981).
11. Zitvogel, L. et al. Dendritic cells or their exosomes are effective biotherapies of cancer. Eur J Cancer 35 Suppl 3, S36–38 (1999).
12. Keller, S. et al. Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Lett 278, 
73–81, doi: 10.1016/j.canlet.2008.12.028 (2009).
13. Thery, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and 
biological fluids. Curr Protoc Cell Biol Chapter 3, Unit 3 22, doi: 10.1002/0471143030.cb0322s30 (2006).
14. Lotvall, J. et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement 
from the International Society for Extracellular Vesicles. Journal of extracellular vesicles 3, 26913, doi: 10.3402/jev.v3.26913 (2014).
15. Cook, K. B., Kazan, H., Zuberi, K., Morris, Q. & Hughes, T. R. RBPDB: a database of RNA-binding specificities. Nucleic Acids Res 39, 
D301–308, doi: 10.1093/nar/gkq1069 (2011).
16. Gezer, U., Tiryakioglu, D., Bilgin, E., Dalay, N. & Holdenrieder, S. Androgen Stimulation of PCA3 and miR-141 and Their Release 
from Prostate Cancer Cells. Cell journal 16, 488–493 (2015).
17. Isin, M. et al. Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease. Frontiers in genetics 6, 168, 
doi: 10.3389/fgene.2015.00168 (2015).
18. Ebert, M. S. & Sharp, P. A. Emerging roles for natural microRNA sponges. Curr Biol 20, R858–861, doi: 10.1016/j.cub.2010.08.052 
(2010).
19. Wang, Y. et al. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-
renewal. Dev Cell 25, 69–80, doi: 10.1016/j.devcel.2013.03.002 (2013).
20. Hessvik, N. P., Phuyal, S., Brech, A., Sandvig, K. & Llorente, A. Profiling of microRNAs in exosomes released from PC-3 prostate 
cancer cells. Biochim Biophys Acta 1819, 1154–1163, doi: 10.1016/j.bbagrm.2012.08.016 (2012).
21. Ohshima, K. et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic 
gastric cancer cell line. PLoS One 5, e13247, doi: 10.1371/journal.pone.0013247 (2010).
22. Gratacos, F. M. & Brewer, G. The role of AUF1 in regulated mRNA decay. Wiley interdisciplinary reviews. RNA 1, 457–473, doi: 
10.1002/wrna.26 (2010).
23. Cao, C. et al. The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein 
HuR to increase levels of beta-catenin in HCC cells. Gastroenterology 148, 415–426 e418, doi: 10.1053/j.gastro.2014.10.012 (2015).
24. Lu, Y. C. et al. ELAVL1 modulates transcriptome-wide miRNA binding in murine macrophages. Cell reports 9, 2330–2343, doi: 
10.1016/j.celrep.2014.11.030 (2014).
25. Connerty, P., Ahadi, A. & Hutvagner, G. RNA Binding Proteins in the miRNA Pathway. Int J Mol Sci 17, doi: 10.3390/ijms17010031 
(2015).
26. Kedde, M. & Agami, R. Interplay between microRNAs and RNA-binding proteins determines developmental processes. Cell Cycle 
7, 899–903 (2008).
27. Balkhi, M. Y. et al. miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR. Sci 
Signal 6, ra63, doi: 10.1126/scisignal.2004177 (2013).
28. Venables, J. P. et al. RBMY, a probable human spermatogenesis factor, and other hnRNP G proteins interact with Tra2beta and affect 
splicing. Hum Mol Genet 9, 685–694 (2000).
29. de Jong, O. G. et al. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. 
Journal of extracellular vesicles 1, doi: 10.3402/jev.v1i0.18396 (2012).
30. Liang, B. et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. Journal of proteomics 80, 171–182, doi: 
10.1016/j.jprot.2012.12.029 (2013).
31. Adamik, B. et al. An association between RBMX, a heterogeneous nuclear ribonucleoprotein, and ARTS-1 regulates extracellular 
TNFR1 release. Biochem Biophys Res Commun 371, 505–509, doi: 10.1016/j.bbrc.2008.04.103 (2008).
32. Hwang, H. W., Wentzel, E. A. & Mendell, J. T. Cell-cell contact globally activates microRNA biogenesis. Proc Natl Acad Sci USA 106, 
7016–7021, doi: 10.1073/pnas.0811523106 (2009).
33. Liu, X. H. et al. Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-
3p in gastric cancer. Mol Cancer 13, 92, doi: 10.1186/1476-4598-13-92 (2014).
34. Song, X. et al. Analysing the relationship between lncRNA and protein-coding gene and the role of lncRNA as ceRNA in pulmonary 
fibrosis. J Cell Mol Med 18, 991–1003, doi: 10.1111/jcmm.12243 (2014).
35. Théry, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and 
biological fluids. Current protocols in cell biology/editorial board, Juan S. Bonifacino … [et al.] Chapter 3 (2006).
36. Webber, J., Steadman, R., Mason, M. D., Tabi, Z. & Clayton, A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. 
Cancer Res 70, 9621–9630, doi: 10.1158/0008-5472.CAN-10-1722 (2010).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 6:24922 | DOI: 10.1038/srep24922
37. Bailey, T. L. et al. MEME SUITE: tools for motif discovery and searching. Nucleic Acids Res 37, W202–208, doi: 10.1093/nar/gkp335 
(2009).
38. Thomas-Chollier, M. et al. RSAT peak-motifs: motif analysis in full-size ChIP-seq datasets. Nucleic Acids Res 40, e31, doi: 10.1093/
nar/gkr1104 (2012).
39. Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 
42, D68–73, doi: 10.1093/nar/gkt1181 (2014).
40. Bailey, T. L. DREME: motif discovery in transcription factor ChIP-seq data. Bioinformatics 27, 1653–1659, doi: 10.1093/
bioinformatics/btr261 (2011).
41. R, W. Inferences based on a skipped correlation coefficient. Journal of Applied Statistics 31, 131–143 (2004).
42. Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res 14, 1188–1190, doi: 
10.1101/gr.849004 (2004).
43. Frith, M. C., Saunders, N. F., Kobe, B. & Bailey, T. L. Discovering sequence motifs with arbitrary insertions and deletions. PLoS 
Comput Biol 4, e1000071, doi: 10.1371/journal.pcbi.1000071 (2008).
44. Cheadle, C., Vawter, M. P., Freed, W. J. & Becker, K. G. Analysis of microarray data using Z score transformation. J Mol Diagn 5, 
73–81, doi: 10.1016/S1525-1578(10)60455-2 (2003).
Author Contributions
N.T. supervised the project, conceived and designed the experiments, and performed laboratory experiments. 
A.A. carried out data preparation, motif enrichment analysis and statistical tests. S.B. performed verification of 
exosomes in the cell lines. A.A., G.H., P.K. and N.T. wrote the manuscript. All authors reviewed and contributed 
edits to the manuscript.
Additional Information
Data Availability:  MicroRNA expression, lncRNA expression and mRNA expression data in all prostate cancer 
cell lines investigated in this study are available on request.
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Ahadi, A. et al. Long non-coding RNAs harboring miRNA seed regions are enriched in 
prostate cancer exosomes. Sci. Rep. 6, 24922; doi: 10.1038/srep24922 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
